Практические Рекомендации По Лекарственному Лечению Меланомы Кожи

Строяковский, Д. Л.; Абрамов, М. Е.; Демидов, Л. В.; Жукова, Н. В.; Новик, А. В.; Орлова, К. В.; Проценко, С. А.; Самойленко, И. В.; Трофимова, О. П.; Харкевич, Г. Ю.; Юрченков, А. Н.

doi:10.18027/2224-5057-2021-11-3s2-16

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Меланома кожи является самой непредсказуемой из всех известных опухолей и составляет 1-3% от всех злокачественных опухолей человека. Данный тип неоплазмы характеризуется разнообразием клинической картины, вариабельностью и полиморфностью течения [4][5][6][7][8][9]. За последние 3 десятилетия в лекарственной терапии злокачественной меланомы предложено несколько схем химиотерапии, однако, эффективность лечения составила не более 22%.…”

Section: Introductionunclassified

“…Возможности генно-молекулярной диагностики позволили получить впечатляющие результаты в лечении меланомы. Именно меланома стала опухолью, открывшей в клинической онкологии дорогу абсолютно новому классу противоопухолевых иммуноонкологических препаратов [6][7][8][9][10][11][12]. Стало понятным, что в патогенезе меланомы вовлечены онкогены и гены-супрессоры, входящие в состав различных сигнальных каскадов.…”

Section: Introductionunclassified

See 1 more Smart Citation

Long-term preservation of the effect of immunotherapy with pembrolizumab as a second line treatment for recurrent skin melanoma

Kogoniya,

Markarova

2024

Medicinskij sovet

View full text Add to dashboard Cite

Over the past two decades, the medical community around the world has been not only a witness, but an active participant in the global transformation of healthcare taking place against the backdrop of the rapid development of modern biomedical technologies. Of course, within the framework of these transformations, several quite independent directions can be distinguished. However, most of them, one way or another, can be united by the concept of “personalized medicine”, which is the subject of discussion among doctors of all specialties, which emphasizes its undoubted relevance. One of the clearest confirmations of this is the rapid growth in the number of review publications devoted to the consideration of issues of a personalized approach in medicine. Using the example of one of the most unpredictable tumors – skin melanoma – in recent years, expressive data have been obtained indicating the effectiveness of individual approaches, personalization of treatment as a result of the use of timely, gene-molecular studies. Despite the fact that in most cases melanoma is localized on the skin and, with a certain degree of oncological alertness, can be detected in the early stages, statistics indicate disappointing facts about the advanced state of the disease. Over the past 40 years, the incidence has increased by 300%. The possibilities of targeted and immunotherapy in the treatment of melanoma in patients with an advanced and unresectable stage of the disease allow long-term effective control of the disease and its symptoms.

show abstract

Section: Introductionunclassified

Long-term preservation of the effect of immunotherapy with pembrolizumab as a second line treatment for recurrent skin melanoma

Kogoniya,

Markarova

2024

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

Subungual melanoma

Bukharov,

Saribekyan,

Vertieva

et al. 2024

Klin. dermatol. venerol.

View full text Add to dashboard Cite

Immuno-oncological drugs application in the treatment of metastatic cutaneous melanoma with lymph nodes metastases of rare localization: a case report

Polyakov

Bolotina

Kornietskaya

et al. 2022

Opuholi golovy i šei

View full text Add to dashboard Cite

Cutaneous melanoma is characterized by an aggressive course associated with a tendency to metastasis. For a long time, the prognosis of patients with metastatic melanoma remained extremely poor. However, the introduction of immunooncological drugs into clinical practice has changed the approaches to the treatment of patients with metastatic melanoma, and fundamentally improved the prognosis and quality of life of such patients, which undoubtedly became a breakthrough in the treatment of this pathology. This article presents a clinical case of the treatment with immunological drugs of a patient with metastatic melanoma of the skin with lymph nodes of rare localization with a complete tumor response.

show abstract

Практические Рекомендации По Лекарственному Лечению Меланомы Кожи

Abstract: .

Cited by 3 publications

References 0 publications

Long-term preservation of the effect of immunotherapy with pembrolizumab as a second line treatment for recurrent skin melanoma

Long-term preservation of the effect of immunotherapy with pembrolizumab as a second line treatment for recurrent skin melanoma

Subungual melanoma

Immuno-oncological drugs application in the treatment of metastatic cutaneous melanoma with lymph nodes metastases of rare localization: a case report

Contact Info

Product

Resources

About